Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Baxter
McKesson
Johnson and Johnson
Colorcon

Last Updated: March 29, 2020

DrugPatentWatch Database Preview

ENJUVIA Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Enjuvia patents expire, and when can generic versions of Enjuvia launch?

Enjuvia is a drug marketed by Aspen and is included in one NDA. There are two patents protecting this drug.

This drug has seventeen patent family members in nine countries.

The generic ingredient in ENJUVIA is estrogens, conjugated synthetic b. There are three drug master file entries for this compound. Additional details are available on the estrogens, conjugated synthetic b profile page.

US ANDA Litigation and Generic Entry Outlook for Enjuvia

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 8, 2021. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for ENJUVIA
International Patents:17
US Patents:2
Applicants:1
NDAs:1
Clinical Trials: 2
Formulation / Manufacturing:see details
DailyMed Link:ENJUVIA at DailyMed
Drug patent expirations by year for ENJUVIA
Drug Sales Revenue Trends for ENJUVIA

See drug sales revenues for ENJUVIA

Generic Entry Opportunity Date for ENJUVIA
Generic Entry Date for ENJUVIA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ENJUVIA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Duramed ResearchPhase 4
Duramed ResearchPhase 3

See all ENJUVIA clinical trials

US Patents and Regulatory Information for ENJUVIA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-001 Dec 20, 2004 DISCN No No   Start Trial   Start Trial Y Y   Start Trial
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-002 Dec 20, 2004 DISCN No No   Start Trial   Start Trial Y Y   Start Trial
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-004 May 10, 2004 DISCN No No   Start Trial   Start Trial Y Y   Start Trial
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-001 Dec 20, 2004 DISCN No No   Start Trial   Start Trial Y Y   Start Trial
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-002 Dec 20, 2004 DISCN No No   Start Trial   Start Trial Y Y   Start Trial
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-005 Apr 27, 2007 DISCN No No   Start Trial   Start Trial Y Y   Start Trial
Aspen ENJUVIA estrogens, conjugated synthetic b TABLET;ORAL 021443-005 Apr 27, 2007 DISCN No No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Premature patent expiration for: ENJUVIA

Expiration due to failure to pay maintenance fee

Patent Number Tradename Expiration Date
  Start Trial ENJUVIA   Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Baxter
McKesson
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.